ライフサイエンスコーパス: BNP

1 BNP concentrations were measured at baseline and were re

2 BNP decreased from 109 [64 to 242] pg/ml to 60 [25 to 17

3 BNP inhibited the fasting-induced increase in total and

4 BNP is a useful biomarker in patients with reduced LVEF,

5 BNP levels are lower in patients with HFPEF than in pati

6 BNP levels in the highest tertile were also associated a

7 BNP levels were related to New York Heart Association fu

8 BNP levels were significantly higher in ischemic compare

9 BNP levels were significantly higher in patients with re

10 BNP ratio (measured BNP/maximal normal BNP value specifi

11 BNP was a strong predictor of outcome, but LVEF was not.

12 BNPs are readily suspended in water, facilitate adherenc

13 BNPs loaded with a potent chemotherapeutic agent [epothi

14 6%) in the intervention group had at least 1 BNP reading of 50 pg/mL or higher.

15 er initial surgical treatment (n = 561, 42%) BNP activation did not impose excess long-term mortality

16 9% (95% confidence interval: 82.0% to 94.5%; BNP level >/=298 pg/ml).

17 8% (95% confidence interval: 88.2% to 97.8%; BNP level, >98 to <298 pg/ml), and 89.9% (95% confidence

18 2% (95% confidence interval: 94.3% to 99.9%; BNP level </=98 pg/ml), 94.8% (95% confidence interval:

19 Achievement of absolute BNP thresholds reduced postdischarge all-cause mortality

20 1.15 to 1.54]; p < 0.0001), whereas absolute BNP was not (p = 0.43).

21 vival determinants, BNP clinical activation (BNP ratio >1) independently predicted mortality after di

22 with blood pressure, whereas those affecting BNP did not, highlighting the blood pressure-lowering ef

23 Although BNP at discharge is predictive of 30-day outcomes, outpa

24 ariable of mortality by univariate analysis (BNP: chi(2)=40.6; P<0.0001 and sTNFR-1: chi(2)=38.9; P<0

25 interval, 1.81-3.78; P for trend <0.001) and BNP (aHR, 1.45; 95% confidence interval, 1.03-2.04; P fo

26 Elevated levels of sTNFR-1 and BNP are strongly associated with outcomes, independent o

27 tegories of hsTnI (aHR range, 0.50-0.60) and BNP (aHR range, 0.42-0.67) with no statistically signifi

28 ity cardiac troponin I (hsTnI) in 12 956 and BNP in 11 076 participants without cardiovascular diseas

29 he signal transducer of the hormones ANF and BNP.

30 hat the cardiac natriuretic peptides ANP and BNP and the guanylate cyclase-linked natriuretic peptide

31 Although ANP and BNP are well-characterized regulators of blood pressure

32 Further, ANP and BNP elicit increases in blood microvessel permeability s

33 ntaining the adjacent genes encoding ANP and BNP harbored 4 independent cis variants with effects spe

34 acetylase 4 (HDAC4), upregulation of ANP and BNP in failing hearts did not require increased histone

35 These effects of ANP and BNP on contractile function were examined further by usi

36 s, the cardiac natriuretic peptides (ANP and BNP) are produced by cardiomyocytes in the developing he

37 rial and brain natriuretic peptides (ANP and BNP, respectively) are cardiac hormones released into th

38 +/- 0.8-fold (P = 0.07, n = 7) with ANP and BNP, respectively.

39 essment of different plasma forms of ANP and BNP.

40 The proBNP1-108 processing enzyme corin and BNP-degrading enzyme dipeptidyl peptidase-4 were reduced

41 adjustments for traditional risk factors and BNP levels, elevated TMAO levels remained predictive of

42 population, baseline cardiac troponin I and BNP were associated with the risk of vascular events and

43 ch as cardiac magnetic resonance imaging and BNP/N-terminal pro-B-type natriuretic peptide, are emerg

44 normal and elevated hs-cTnI (>26.2 ng/L) and BNP (>100 pg/mL) were also studied.

45 Age, sex, and BNP and TnI concentrations were similar between the 25 p

46 and creatine kinase-MB (CK-MB), and TnI and BNP by CART.

47 ve EuroSCORE risk with postoperative TNT and BNP after surgery allows for improved prediction of 1-ye

48 Postoperative TNT and BNP are strong predictors of 1-year events after on-pump

49 ed the net reclassification index of TNT and BNP in addition to the EuroSCORE.

50 s to assess the independent value of TNT and BNP to predict 12-month outcome after cardiac surgery wi

51 ssification index of the addition of TNT and BNP to the EuroSCORE was 0.276 (95% confidence interval,

52 We evaluated postoperative TNT and BNP, the EuroSCORE, and postoperative complications as p

53 outpatient setting measured their weight and BNP levels daily for 60 days with a finger-stick test.

54 In this large series of patients with AS, BNP clinical activation was associated with excess long-

55 tration in ascitic fluid, serum, and ascites BNP.

56 1.21) and results did not differ by baseline BNP concentration.

57 Elevated baseline BNP was associated with a significant 68% (P=0.007) and

58 Main Outcome and Measures: Baseline BNP; subsequent hospitalization for heart failure or dea

59 ng the cohort of 1197 patients with baseline BNP data enrolled in MADIT (Multicenter Automated Defibr

60 ants (SDS, 8 M urea, DTT, or trypsin) before BNP.

61 Correlations between BNP measures weakened over time, and the dispersion betw

62 akened over time, and the dispersion between BNP measures grew.

63 In AS, the link between BNP levels and clinical outcome is in dispute.

64 the context of multivariable analysis, both BNP and sTNFR-1 contributed independent prognostic infor

65 ve associations between temperature and both BNP and CRP-predictors of heart failure prognosis and se

66 ight monitoring is complementary to BNP, but BNP changes correspond to larger changes in risk, both u

67 s, the prognostic information contributed by BNP (chi(2)=6.0; P=0.049) and sTNFR-1 (chi(2)=8.8; P=0.0

68 in the cardiovascular protection provided by BNP.

69 ailable data suggests that care supported by BNP/NT-proBNP-guided HF treatment-as an adjunct to stand

70 f patients with hypertrophic cardiomyopathy, BNP was an independent predictor of morbidity and mortal

71 VSD, but would still miss one in four cases (BNP: sensitivity 76%, NPV 97%, cut-off 145 pg/ml; NT-pro

72 out tests but would miss one in three cases (BNP: sensitivity 67%, NPV 86%, cut-off 115 pg/ml; NT-pro

73 Achievement of percentage-change BNP thresholds reduced the composite outcome (5 of 6 stu

74 nsitivity was observed in lean mice, chronic BNP infusion improved blood glucose control and insulin

75 Although circulating BNP levels are higher in women, when compared to age-mat

76 M to a proportional hazards model containing BNP and left ventricular ejection fraction.

77 A total of 6,934 daily BNP values were recorded, with a median of 46 measures p

78 NP value specific to age and sex) >1 defined BNP clinical activation.

79 er adjustment for all survival determinants, BNP clinical activation (BNP ratio >1) independently pre

80 normal, perhaps contributing to differential BNP metabolism in HF.

81 Elevated BNP and hs-cTnI identify candidates for targeted risk re

82 e apparent evolution of HFpEF where elevated BNP is prevalent, MF was similarly prevalent in those wi

83 Among patients at risk of heart failure, BNP-based screening and collaborative care reduced the c

84 R-1 in the Hypothesis 1 cohort, and 0.15 for BNP and 0.30 for sTNFR-1 in the Hypothesis 2 cohort, ref

85 ment for the primary end points was 0.29 for BNP and 0.21 for sTNFR-1 in the Hypothesis 1 cohort, and

86 tivation and 2.10 [95% CI: 1.32 to 3.36] for BNP ratio of 1 to 2, 2.25 [95% CI: 1.31 to 3.87] for BNP

87 o of 2 to 3, 3.93 [95% CI: 2.40 to 6.43] for BNP ratio of >/=3).

88 adjusted HR: 2.35 [95% CI: 1.57 to 3.56] for BNP clinical activation and 2.10 [95% CI: 1.32 to 3.36]

89 P (area under the curve of 0.85 vs. 0.74 for BNP) and Kaplan-Meier curves (log rank: 17.5 vs. 9.95).

90 o of 1 to 2, 2.25 [95% CI: 1.31 to 3.87] for BNP ratio of 2 to 3, 3.93 [95% CI: 2.40 to 6.43] for BNP

91 e a possible shared allelic architecture for BNP with aldosterone-renin ratio, and motivate further s

92 ) ng/L for hs-cTnI and 39 (15, 94) pg/mL for BNP.

93 blood pressure with conflicting results for BNP.

94 s with HF with reduced LVEF, but for a given BNP level, the prognosis in patients with HFPEF is as po

95 atients with hypertrophic cardiomyopathy had BNP obtained in conjunction with echocardiography and cl

96 For undifferentiated HF, BNP or NT-proBNP were adequate rule-out tests but would

97 Biomarkers were less useful for HFpEF (BNP: sensitivity 63%, specificity 61%, cut-off 110 pg/ml

98 Multivariable analysis revealed that high BNP and low peak VO(2) were independently associated wit

99 x survival in heart recipients, whereas high BNP levels indicate worse outcome in this group of patie

100 Higher BNP activation was associated with higher mortality (p <

101 Higher BNP is associated with mortality and cardiovascular and

102 Higher mortality with higher BNP clinical activation, even in asymptomatic patients,

103 This study highlights BNP's vasoprotective propensity, bringing to light a pos

104 At 1:1-2:1 RProt:HMP, BNPs showed appreciable turbidity, a nanometric diameter

105 This pilot study demonstrates that home BNP testing is feasible and that trials using home monit

106 ject) placebo once and 3.0 pmol/kg/min human BNP-32 once administered as a continuous infusion during

107 MF was associated with disease severity (ie, BNP) and outcomes.

108 The observed increase in BNP concentration was proportional to the number of effe

109 isplayed significantly greater reductions in BNP (26% reduction) levels compared with implantable car

110 r could promote significant LA protection in BNPs.

111 justing for potential confounders, including BNP, PH was found to be associated with HF hospitalizati

112 and PASP and potential mediators, including BNP (B-type natriuretic peptide) and endothelin-1.

113 For baseline models including BNP, the addition of H/M did not significantly increase

114 y, we investigated the impact of intravenous BNP administration on appetite-regulating hormones and s

115 At 3 months, the latest BNP plasma level (OR: 0.14 [95% CI: 0.02 to 0.94] per lo

116 The hazard ratio per unit increase of ln BNP was 1.84, and the hazard ratio on a day of weight ga

117 HFpEF, ECV was associated with baseline log BNP (disease severity surrogate) in multivariable linear

118 explained 0.4% and 1.9% of variation in log BNP concentration, respectively.

119 vel (OR: 0.14 [95% CI: 0.02 to 0.94] per log BNP; p = 0.047) was the strongest predictor of LVRR.

120 th peak VO(2) 10 to 14 mL/min per kg and low BNP levels have a VAD-free or HTx-free survival similar

121 D was highest among those who maintained low BNP levels or in whom BNP level at 1-year was reduced.

122 combining MELD score exceeding 25 and pre-LT BNP concentration exceeding 155 pg/mL had a 27% ICU mort

123 Pre-LT BNP concentration, adjusted on model of end-stage liver

124 66-0.93), the optimal cutoff value of pre-LT BNP serum level to predict ICU mortality was 155 pg/mL w

125 In cirrhotic patients, pre-LT BNP serum level was an independent predictor of post-LT

126 Early geometric mean BNP concentrations were similar at 72 h but significantl

127 BNP ratio (measured BNP/maximal normal BNP value specific to age and sex) >1

128 Median BNP and NT-proBNP levels in the study cohort (mean age 4

129 m(2); mean gradient 36 +/- 19 mm Hg), median BNP level was 252 pg/ml (interquartile range: 98 to 592

130 uivalent for carbon dioxide <45 l/min/l/min, BNP level toward "normal," echocardiograph and/or cardia

131 g/ml (interquartile range: 98 to 592 pg/ml); BNP ratio 2.46 (interquartile range 1.03 to 5.66); eject

132 In 1,331 patients with degenerative MR, BNP was prospectively measured at diagnosis and expresse

133 ue formulation of bioadhesive nanoparticles (BNPs) can interact with mesothelial cells in the abdomin

134 del UV filter--in bioadhesive nanoparticles (BNPs) prevents epidermal cellular exposure to UV filters

135 bout the design of biopolymer nanoparticles (BNPs) for polyunsaturated fatty acid (PUFA) vehiculizati

136 ved xenografts compared with free EB and non-BNPs loaded with EB.

137 BNP ratio (measured BNP/maximal normal BNP value specific to age and sex) >1 defined BNP clinic

138 , and lack of accounting for shifting normal BNP ranges with age and sex.

139 ight-year survival was 62 +/- 3% with normal BNP levels, 44 +/- 3% with BNP ratio of 1 to 2 (adjusted

140 Compared to normotensive, BNP(1-32) and N-terminal proBNP(1-76) (NT-proBNP(1-76))

141 Although no acute effect of brain NP (BNP) on insulin sensitivity was observed in lean mice, c

142 mmonly used thresholds were a brain-type NP (BNP) level of 250 pg/mL or less or an amino-terminal pro

143 Obtaining BNPs involved the electrostatic deposition of high metho

144 The diagnostic accuracy of BNP, cTnT, and s-cTnI for the diagnosis of ischemic AHF,

145 ent with subcutaneous (SC) administration of BNP in experimental HF resulted in improved cardiovascul

146 (95% confidence interval, 1.47-3.15) and of BNP >790 ng/L was 2.44 (95% confidence interval, 1.65-3.

147 To determine the association of BNP with the risk of diabetes, we conducted a prospectiv

148 mprove our knowledge of the genetic basis of BNP variation in blacks, demonstrate a possible shared a

149 assessed the cardiovascular consequences of BNP deletion in genetically null (Nppb-/-) female rat li

150 by genotype, and cardiorenal consequences of BNP knock out remained minor.

151 The processing and degradation of BNP molecular forms were altered but complete in HF, whi

152 This study assessed the effect of BNP activation on mortality in a large, multicenter coho

153 studies suggest direct metabolic effects of BNP.

154 Simultaneous elevations of BNP and hs-cTnI over clinical cutoffs were strongly asso

155 demonstrate that the N-terminal extension of BNP is essential to virus viability not only for directi

156 nificance of this region on the functions of BNP and virus viability.

157 rognostic values (p < 0.0001) independent of BNP and traditional risk factors.

158 ce of appropriate clinical interpretation of BNP levels in managing patients with AS.

159 Both plasma levels of BNP (chi(2)=30.3) and sTNFR-1 (chi(2)=45.5) were highly

160 tality was lower across increasing levels of BNP (log-rank test, p = 0.002).

161 erature was associated with higher levels of BNP beginning with 2-day moving averages and reached sta

162 Importantly, if similar levels of BNP were compared across the whole spectrum of LVEF, and

163 t only for directing nuclear localization of BNP but also for regulating viral mRNA transcription and

164 are involved in the nuclear localization of BNP, with the entire N-terminal extension required for t

165 A program of prospective measurement of BNP levels with Doppler echocardiographic AS assessment

166 -terminal (NT)-proBNP, a cleavage product of BNP, was inversely associated with adiposity, fasting gl

167 ic peptide (BNP) or N-terminal prohormone of BNP, mild-to-moderate renal insufficiency, and systolic

168 the cardiovascular protective propensity of BNP in females is poorly understood.

169 ibrotic, and anti-hypertrophic properties of BNP are well established in male animal models.

170 outcome were higher with higher quartiles of BNP after adjustment and remained statistically signific

171 Quartiles of BNP and high-sensitivity cardiac troponin I (hs-cTnI) we

172 1-108) along with a concomitant reduction of BNP(1-32) and NT-proBNP(1-76) in the early stages of hyp

173 and upon recent findings that this region of BNP is required for nuclear localization of the protein.

174 aining mutations in the first 10 residues of BNP demonstrated few differences in nuclear localization

175 ort a direct and important metabolic role of BNP in humans.

176 ailure to account for the normal shifting of BNP ranges with aging in men and women, not using hard e

177 te for the first time that the N terminus of BNP is involved in regulating viral mRNA transcription a

178 the metabolite panel was better than that of BNP (area under the curve of 0.85 vs. 0.74 for BNP) and

179 tudy was to evaluate the clinical utility of BNP in patients with CHD.

180 seen when assessing the predictive value of BNP and sTNFR-1 in patients assigned to STICH Hypothesis

181 However, the value of BNP as a diagnostic and prognostic marker for patients w

182 er kg were dichotomized by a cutoff value of BNP of 506 pg/mL, those with BNP<506 pg/mL was equivalen

183 resented a strong rationale for the value of BNP- and NTproBNP-guided HF management.

184 Data on BNP measurements and cardiac function parameters were ex

185 Although the sunblock based on BNPs contained less than 5 wt% of the UV-filter concentr

186 R: 0.68; 95% CI: 0.52 to 0.89; p = 0.003) or BNP ratio of >2 (HR: 0.56; 95% CI: 0.47 to 0.66; p < 0.0

187 alance, we tested the hypothesis that ANP or BNP (100 nM) would likewise elevate lymphatic permeabili

188 d consistent regardless of baseline hsTnI or BNP concentrations.

189 cts specific to either midregional proANP or BNP and a rare missense single nucleotide polymorphism i

190 ), BNP, aminoterminal proBNP (NT-proBNP), or BNP:NT-proBNP ratio.

191 Here we used Blue Native PAGE (BNP) and Western blots to study native htt in human post

192 tomatic treated primary prevention patients, BNP screening is able to identify existing silent cTOD.

193 on between serum B-type natriuretic peptide (BNP) activation and survival after the diagnosis of aort

194 plasma levels of B-type natriuretic peptide (BNP) and cardiac troponin I are associated with adverse

195 mic stress using B-type natriuretic peptide (BNP) and cardiomyocyte damage using 2 different cardiac

196 asurements of 1) B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-p

197 tionship between B-type natriuretic peptide (BNP) and survival in patients with hypertrophic cardiomy

198 Measurement of B-type natriuretic peptide (BNP) and the cardiological examination were repeated at

199 oncentrations of B-type natriuretic peptide (BNP) and to determine how these concentrations correlate

200 of postoperative B-type natriuretic peptide (BNP) are scarce.

201 c implications of brain natriuretic peptide (BNP) assessment in patients with mildly symptomatic hear

202 -c3 (NFATc3), and brain natriuretic peptide (BNP) compared to controls.

203 heart failure and brain natriuretic peptide (BNP) concentration at baseline.

204 iac troponin and B-type natriuretic peptide (BNP) concentrations are associated with adverse cardiova

205 tein (hsCRP) and B-type natriuretic peptide (BNP) concentrations at 72 h and 12 weeks, and troponin I

206 Brain natriuretic peptide (BNP) has an established role in cardiovascular disease (

207 B-type natriuretic peptide (BNP) has been proposed as a tool for predicting and dete

208 eptide (ANP) and B-type natriuretic peptide (BNP) in heart tissue may also contribute to DXR resistan

209 gnostic value of B-type natriuretic peptide (BNP) in patients with heart failure with preserved eject

210 eptide (ANP) and B-type natriuretic peptide (BNP) in response to mechanical stretching, making them u

211 B-type natriuretic peptide (BNP) is a guanylyl cyclase A (GC-A) agonist.

212 B-type natriuretic peptide (BNP) is a useful prognostic marker in patients with hear

213 ies suggest that B-type natriuretic peptide (BNP) is cardioprotective; however, in clinical studies,

214 ven elevated brain-type natriuretic peptide (BNP) level; 160 had HFpEF by documented clinical diagnos

215 ncentrations and B-type natriuretic peptide (BNP) levels (r = 0.23; p < 0.001).

216 ther preoperative brain natriuretic peptide (BNP) levels predict postoperative AKI among patients und

217 hether admission B-type natriuretic peptide (BNP) levels predict the development of CI-AKI.

218 suggesting that B-type natriuretic peptide (BNP) may predict outcomes of mitral regurgitation (MR) a

219 ograph, increased brain natriuretic peptide (BNP) or N-terminal prohormone of BNP, mild-to-moderate r

220 Serum B-type natriuretic peptide (BNP) plays an important role in the diagnosis of HF.

221 Brain natriuretic peptide (BNP) serum concentration has been shown to be a preopera

222 r-1 (sTNFR-1) and brain natriuretic peptide (BNP) were highly predictive of the primary outcome varia

223 roponin I (TnI), B-type natriuretic peptide (BNP), and creatine kinase-MB (CK-MB), and TnI and BNP by

224 normalization of B-type natriuretic peptide (BNP), and hemodynamics with right atrial pressure <8 mm

225 ating RBP4, TTR, B-type natriuretic peptide (BNP), and troponin I (TnI) concentrations and electrocar

226 eptide (ANP) and B-type natriuretic peptide (BNP), have central roles in sodium and blood pressure re

227 NP) and B-type or brain natriuretic peptide (BNP), in the general community, focusing on their relati

228 peptide (ANP) and brain natriuretic peptide (BNP), is a hallmark for maladaptive remodeling of the LV

229 eported that pro-B-type natriuretic peptide (BNP)-1-108 circulates and is processed to mature BNP1-32

230 value similar to B-type natriuretic peptide (BNP).

231 ative stress, and brain natriuretic peptide (BNP).

232 ion fraction and b-type natriuretic peptide (BNP).

233 iuretic peptides (brain natriuretic peptide [BNP] >/= 400 pg/mL or N -terminal pro-BNP [NT-proBNP] >/

234 Assessment with B-type Natriuretic Peptide [BNP] In the Home [HABIT]; NCT00946231).

235 however, in clinical studies, higher plasma BNP concentrations have been associated with incident ca

236 sed in a model with clinical indicators plus BNP, cTnI, ST2, PAPP-A, and MPO (each p</=0.01) [correct

237 Preoperative BNP level is associated with postoperative AKI in high-r

238 LT for cirrhosis and for whom a preoperative BNP serum dosage was available between January 2011 and

239 ypes of patients and surgeries, preoperative BNP may be a valuable component of future efforts to imp

240 rohormone of brain naturetic peptide (NT pro-BNP) were low and did not change with acute exercise or

241 D with elevated TRV alone or elevated NT-pro-BNP alone, and for patients with SCD with RHC-confirmed

242 NT-pro-BNP concentrations decreased significantly and similarly

243 l to or greater than 2.5 m/second, an NT-pro-BNP level equal to or greater than 160 pg/ml, or RHC-con

244 sessed changes in N-terminal pro-BNP (NT-pro-BNP) from baseline to 6 months.

245 rminal pro-brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension (PH) diagnosed by

246 eptor II, pro-brain natriuretic peptide (pro-BNP), and cardiac troponin T showed significant linear t

247 We also assessed changes in N-terminal pro-BNP (NT-pro-BNP) from baseline to 6 months.

248 ptide [BNP] >/= 400 pg/mL or N -terminal pro-BNP [NT-proBNP] >/= 1600 pg/mL), and signs and symptoms

249 ociated with midregional proANP (MR-proANP), BNP, aminoterminal proBNP (NT-proBNP), or BNP:NT-proBNP

250 anced reclassification, neither H/M results, BNP levels, nor left ventricular ejection fraction inter

251 Eight weeks of chronic SC BNP resulted in a greater reduction of LV systolic and d

252 oof of concept study comparing 8 weeks of SC BNP (10 mug/kg bid) (n = 20) with placebo (n = 20) in pa

253 Both CMR and serial BNP testing provide a better prediction of LVRR in recen

254 Serum BNP is more accurate than ascites analyses in the diagno

255 ith MELD score exceeding 25 and pre-LT serum BNP level less than 155 pg/mL survived, whereas patients

256 ites could be streamlined by obtaining serum BNP as an initial test and could forego the need for dia

257 Measurement of serum BNP at hospital admission may help identify patients who

258 cites from other causes of ascites was serum BNP.

259 Subcutaneous BNP represents a novel, safe, and efficacious protein th

260 management together with a goal to suppress BNP or NT-proBNP concentrations leads to greater applica

261 ynthetic-bioinformatic natural products (syn-BNPs).

262 Using this approach, we screened syn-BNPs inspired by nonribosomal peptide synthetases agains

263 NP levels (dichotomized at the upper tertile BNP of 120 pg/mL) on the risk of HF or death was assesse

264 Therefore, we hypothesized that BNP would be useful in the differential diagnosis of asc

265 Mediation analysis showed that BNP and endothelin-1 explained 56% and 40%, respectively

266 In the BNP-driven group, furosemide and acetazolamide were give

267 Defects in the BNP/GC-A/cGMP pathway may play a role in arteriopathies

268 Moreover, the BNP-based sunblock significantly reduced double-stranded

269 flicting evidence as to the functions of the BNP N-terminal extension; however, this has never been a

270 In certain studies of this BNP or NT-proBNP 'guided' approach, patients treated wit

271 Patients and physicians were blinded to BNP levels.

272 Daily weight monitoring is complementary to BNP, but BNP changes correspond to larger changes in ris

273 tio 1.17), and higher median log-transformed BNP (hazard ratio 2.26) were associated with worse longe

274 Median log-transformed BNP and LV-GLS were 4.04 (absolute brain natriuretic pep

275 ddition of LV-GLS and median log-transformed BNP to a clinical model (Society of Thoracic Surgeons sc

276 ariable-adjusted logarithmically transformed BNP controlling for relevant covariates and population s

277 were 39 (18.4%) intervals of upward trending BNP corresponding to a risk increase of 59.8% and 64 (30

278 st that assessment of baseline and follow-up BNP provides important prognostic implications in patien

279 cal, laboratory, and angiographic variables, BNP remained a significant independent predictor of CI-A

280 However, NP of influenza B viruses (BNP) contains an evolutionarily conserved N-terminal 50-

281 (P = 0.005) and frequency (P = 0.006), while BNP augmented both parameters by approximately 2-fold (P

282 ose who maintained low BNP levels or in whom BNP level at 1-year was reduced.

283 creased in pre-hypertension (p < 0.05), with BNP(1-32) significantly decreased in stage 1 as well (p

284 2; 95% CI: 1.63 to 2.75), and 15 +/- 2% with BNP ratio of >/=3 (adjusted HR: 2.43; 95% CI: 1.94 to 3.

285 /- 3% with normal BNP levels, 44 +/- 3% with BNP ratio of 1 to 2 (adjusted HR: 1.49; 95% CI: 1.17 to

286 1.49; 95% CI: 1.17 to 1.90), 25 +/- 4% with BNP ratio of 2 to 3 (adjusted HR: 2.12; 95% CI: 1.63 to

287 d by a similarly high margin (p = 0.54) with BNP ratio of <2 (HR: 0.68; 95% CI: 0.52 to 0.89; p = 0.0

288 nyltransferase 4 gene GALNT4 associated with BNP:NT-proBNP ratio but not with BNP or midregional proA

289 ember 2010 for 56 case calves diagnosed with BNP between 17 March and 7 June of the same year.

290 e MR, incurred similar excess mortality with BNP activation.

291 ciated with BNP:NT-proBNP ratio but not with BNP or midregional proANP, suggesting effects on the pos

292 Intervention-group participants with BNP levels of 50 pg/mL or higher underwent echocardiogra

293 (control condition; n=677) or screening with BNP testing (n=697).

294 d obesity status; findings were similar with BNP.

295 was a survival difference between those with BNP>/=506 and <506 pg/mL (1 year: 77.2% versus 56.1%; P=

296 8% versus 87.2%; P=0.61), whereas those with BNP>/=506 showed worse VAD-free or HTx-free survival (1

297 cutoff value of BNP of 506 pg/mL, those with BNP<506 pg/mL was equivalent to post-HTx survival (1 yea

298 The effect of elevated baseline and 1-year BNP levels (dichotomized at the upper tertile BNP of 120

299 ath as compared with patients in whom 1-year BNP levels were high.

300 Patients with CRT-D in whom 1-year BNP levels were reduced or remained low experienced a si